Penn Medicine Heart and Vascular Center, where our primary goal is to lead the way in innovative care, enhance clinical outcomes, and deliver exceptional healthcare to patients with or at risk for heart and vascular disease. In the latest U.S. News & World Report Best Hospitals rankings for Cardiology and Heart Surgery in 2020-2021, The Hospital of the University of Pennsylvania-Penn Presbyterian earned the prestigious #1 spot in Pennsylvania and ranked #19 nationwide.
Our Heart Valve Disease Program at Penn Medicine is one of the largest in the mid-Atlantic region. By bringing together a team of highly skilled cardiac surgeons and interventional cardiologists, we offer a comprehensive range of treatments for all types of cardiac valve disorders, including combined procedures and valve-sparing techniques, throughout the progression of the disease.
Penn Medicine has been a pioneer in transcatheter aortic valve replacement (TAVR) since our first procedure in 2007, and we are now recognized as one of the top five TAVR programs in the country. Our expertise in aortic valve surgery is also acknowledged as high-performing by U.S. News & World Report. Additionally, we have been at the forefront of mitral valve surgery, performing the second MitraClip procedure in the United States back in 2003. Our institution is renowned for its advancements in robotic and minimally invasive approaches to mitral valve surgery.